| Literature DB >> 32438426 |
Rebecca T Leeb1, Robyn A Cree1, Laura Aird2, Roberta L DeBiasi3, Rita W Driggers4, Elizabeth Garbarczyk5, Lynne M Mofenson6, Scott Needle7, Jeannie Rodriguez8,9, Christine Curry10, Francisco García11, Shana Godfred-Cato1, Debra Hawks12, Elizabeth Rosenblum13, Eric Dziuban14, Mark Hudak15.
Abstract
Emergency response to emerging threats with the potential for vertical transmission, such as the 2015 to 2017 response to Zika virus, presents unique clinical challenges that underscore the need for better communication and care coordination between obstetric and pediatric providers to promote optimal health for women and infants. Published guidelines for routine maternal-infant care during the perinatal period, and models for transitions of care in various health care settings are available, but no broad framework has addressed coordinated multidisciplinary care of the maternal-infant dyad during emergency response. We present a novel framework and strategies to improve care coordination and communication during an emergency response. The proposed framework includes (1) identification and collection of critical information to inform care, (2) key health care touchpoints for the maternal-infant dyad, and (3) primary pathways of communication and modes of transfer across touchpoints, as well as practical strategies. This framework and associated strategies can be modified to address the care coordination needs of pregnant women and their infants with possible exposure to other emerging infectious and noninfectious congenital threats that may require long-term, multidisciplinary management. KEY POINTS: · Emerging congential threats present unique coordination challenges for obstetric and pediatric clinicians during emergency response.. · We present a framework to help coodinate care of pregnant women/infants exposed to congenital threats.. · The framework identifies critical information to inform care, health care touchpoints, and communication/information transfer pathways.. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Entities:
Mesh:
Year: 2020 PMID: 32438426 PMCID: PMC7416207 DOI: 10.1055/s-0040-1712104
Source DB: PubMed Journal: Am J Perinatol ISSN: 0735-1631 Impact factor: 1.862
Fig. 1Children's interdisciplinary care coordination (ChICC) framework. a Icons clockwise from top right represent: letter, phone, smart phone applications, health passport, in-person exchange, email; center: postal service. b Top icon: electronic upload; bottom: electronic linkage.
Critical information about Zika virus exposure of the maternal-infant dyad to be communicated and touchpoints where this information can be queried to inform coordination of care
| Prenatal care | Delivery facility | Newborn nursery | Pediatric home | Provides information about | |
|---|---|---|---|---|---|
| Mother and Father | |||||
| Location of travel to/residence in area with possible Zika virus transmission |
X
|
◯
| ◯ | ◯ | Risk for fetal exposure |
| Date(s) of travel and/or time of residence | X | ◯ | ◯ | ◯ | Timing of fetal exposure |
| Pregnancy trimester of possible exposure | X | ◯ | ◯ | ◯ | Timing of fetal exposure |
| Was maternal Zika testing performed? | X | ◯ | ◯ | ◯ | |
| Date(s) of testing: | X | ◯ | ◯ | ◯ | Timing and type of maternal laboratory testing. Was maternal testing done according to available clinical guidance? |
| Laboratory result(s): | X | ◯ | ◯ | ◯ | Maternal Zika virus infection status |
| Was paternal Zika testing performed? | X | ◯ | ◯ | ◯ | |
| Date(s) of testing: | X | ◯ | ◯ | ◯ | Timing and type of paternal laboratory testing. Was paternal testing done according to available clinical guidance? |
| Laboratory result(s): | X | ◯ | ◯ | ◯ | Paternal Zika virus infection status |
| Plain language interpretation of laboratory result(s) | X | ◯ | ◯ | ◯ | Clear explanation of laboratory results |
| Actionable next steps based on laboratory finding(s) | X | ◯ | ◯ | ◯ | Critical action steps for the next provider and patient |
| Fetus | |||||
| Was routine and/or prescribed fetal imaging (ultrasound or MRI) performed? | X | ◯ | ◯ | ◯ | Possible atypical fetal development |
| Fetal imaging date(s), type(s) and result(s) | X | ◯ | ◯ | ◯ | Was testing done according to available clinical guidance? |
| Interpretation of imaging result(s) | X | ◯ | ◯ | ◯ | Is there evidence of atypical fetal development consistent with Zika virus exposure? |
| Actionable next steps based on imaging finding(s) | X | ◯ | ◯ | ◯ | Critical action steps for the next provider and patient |
| Infant | |||||
| Date of birth | X | ◯ | ◯ | ||
| Was routine TORCH screening performed? | X | Was testing done according to available clinical guidance? | |||
| Was testing for aneuploidy performed? | X | ||||
| Was Zika laboratory testing of infant performed? | X | ◯ | ◯ | ||
| Date(s) of testing: | X | ◯ | ◯ | Timing and type of infant testing | |
| Laboratory result(s): | X | ◯ | ◯ | Congenital Zika virus exposure status | |
| Plain language interpretation of laboratory result(s) | X | ◯ | ◯ | Clear explanation of laboratory results | |
| Actionable next steps based on laboratory finding(s) | X | ◯ | ◯ | Critical action steps related to laboratory results for the next provider and patient | |
| Follow-up testing recommended | X | ◯ | ◯ | Recommended clinical test(s) and specialist referral(s) | |
|
Was comprehensive physical exam conducted in accordance with published clinical guidance
| X | ◯ | ◯ | Was exam done according to available clinical guidance? | |
| Date(s) of physical exam for: | X | ◯ | ◯ | Timing and type of exam | |
| Results of physical exam for: | X | ◯ | ◯ | Comparison to typical development | |
| Date(s) of: | X | ◯ | ◯ | Timing and type of exam | |
| Results of: | X | ◯ | ◯ | Evidence of atypical results consistent with congenital Zika exposure | |
| Interpretation physical evaluation including screening | X | ◯ | ◯ | Clear explanation typical and atypical results | |
| Recommended follow-up evaluation(s) | X | ◯ | ◯ | Recommended follow-up and specialist referral | |
|
Developmental monitoring and screening
| X | X | Comparison to typical development | ||
| Date of appointment(s) | X | X | |||
| Notable result(s) | X | X | |||
| Interpretation of new information | X | X | Clear explanation typical and atypical results | ||
| Actionable follow-up steps | X | X | Recommended follow-up and specialist referral | ||
| Health care provider | |||||
| Point of contact for maternal primary obstetric healthcare provider | X | X | X | X | Point of contact for questions about maternal history |
| Point of contact for primary pediatric healthcare provider | X | X | X | X | Point of contact for pediatric medical home |
| Contact information for specialist referral(s) | X | X | X | X | Next steps for patient |
Abbreviations: ABR, automated auditory brainstem response; CSF, cerebrospinal fluid; IgM, Immunoglobulin M; MRI, magnetic resonance imaging; NAT, nucleic acid test; PRNT, plaque reduction neutralization test; TORCH, screening for toxoplasmosis, other (HIV, hepatitis viruses, varicella, parvovirus), rubella, cytomegalovirus, herpes simplex, and syphilis.
X = primary touchpoint for collection of critical information.
◯ = secondary touchpoint for collection of critical information.
May also be “Zika polymerase chain reaction (PCR) (urine and blood).”
CDC clinical guidance states jurisdictions should make informed decisions about the utility of PRNT depending on the prevalence of dengue and Zika virus infection and observed performance of PRNT to confirm IgM test results. Available at: https://www.cdc.gov/pregnancy/zika/testing-follow-up/documents/Testing_Algorithm.pdf . Accessed: April 28, 2020.
See “Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection–United States,” October 2017 for additional information on recommendations and timing. Available at: https://www.cdc.gov/mmwr/volumes/66/wr/mm6641a1.htm?s_cid=mm6641a1_w . Accessed: April 28, 2020.
Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend that all infants receive developmental monitoring as part of routine care to ensure they are achieving appropriate developmental milestones. Available at: https://www.cdc.gov/ncbddd/actearly/hcp/index.html and https://www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Screening/Pages/Screening-Recommendations.aspx and https://www.cdc.gov/pregnancy/zika/testing-follow-up/evaluation-testing.html . Accessed: February 1, 2019.